Several phase II clinical trials using an EGFR inhibitor (gefitinib or erlotinib) as monotherapy on advanced breast cancers (not necessarily TNBC) found minimal benefits from treatment, reporting PR rates of 0–3% and no reported CRs [103,104,105]. This evidence concerns the gene EGFR and breast cancer.